Feb 02, 2023
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
Jan 26, 2023
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
Jan 03, 2023
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference